Cited 11 times in
Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구교철 | - |
dc.contributor.author | 나군호 | - |
dc.contributor.author | 이광석 | - |
dc.contributor.author | 이종수 | - |
dc.contributor.author | 정병하 | - |
dc.contributor.author | 하지수 | - |
dc.contributor.author | 홍성준 | - |
dc.contributor.author | 한경석 | - |
dc.contributor.author | 하윤수 | - |
dc.date.accessioned | 2019-12-18T01:00:39Z | - |
dc.date.available | 2019-12-18T01:00:39Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0724-4983 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173320 | - |
dc.description.abstract | PURPOSE: To investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) for the selection of the optimal sequencing strategy using docetaxel and androgen receptor axis-targeted (ARAT) agents in patients with M0 or M1 castration-resistant prostate cancer (CRPC). Currently, there is a need to identify biomarkers to guide optimal sequential treatment in CRPC. METHODS: This multicenter, retrospective analysis included 303 consecutive patients initially diagnosed with M0 or M1 CRPC between September 2009 and March 2017. Of these, 52 (17.2%) patients received pre-docetaxel ARAT agents and 189 (62.4%) patients received post-docetaxel ARAT agents. The prognostic ability of NLR at CRPC diagnosis regarding radiographic progression-free survival (rPFS) and cancer-specific survival (CSS) were investigated. For the analysis, the NLR level was dichotomized at 2.5, and evaluated according to sequencing strategy. RESULTS: Multivariate analysis revealed NLR ≥ 2.5 as an independent predictor of a lower risk for CSS. During the median follow-up of 18.5 months, patients with NLR ≥ 2.5 exhibited significantly lower 1-year rPFS (p = 0.011) and 2-year CSS rates (p = 0.005) compared to patients with NLR < 2.5. Among patients with NLR < 2.5, the post-docetaxel ARAT agent sequencing group exhibited higher 1-year rPFS (p = 0.031) and 2-year CSS (p = 0.026) rates compared to the pre-docetaxel ARAT agent sequencing group. Among patients with NLR ≥ 2.5, rPFS and CSS rates were comparable regardless of ARAT agent sequencing. CONCLUSION: NLR ≥ 2.5 at CRPC diagnosis is associated with a lower risk for CSS. Patients with NLR < 2.5 should primarily be offered docetaxel considering the survival benefit of docetaxel-to-ARAT agent sequencing. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | WORLD JOURNAL OF UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Kyo Chul Koo | - |
dc.contributor.googleauthor | Jong Soo Lee | - |
dc.contributor.googleauthor | Jee Soo Ha | - |
dc.contributor.googleauthor | Kyung Suk Han | - |
dc.contributor.googleauthor | Kwang Suk Lee | - |
dc.contributor.googleauthor | Yoon Soo Hah | - |
dc.contributor.googleauthor | Koon Ho Rha | - |
dc.contributor.googleauthor | Sung Joon Hong | - |
dc.contributor.googleauthor | Byung Ha Chung | - |
dc.identifier.doi | 10.1007/s00345-019-02658-1 | - |
dc.contributor.localId | A00188 | - |
dc.contributor.localId | A01227 | - |
dc.contributor.localId | A02668 | - |
dc.contributor.localId | A05500 | - |
dc.contributor.localId | A03607 | - |
dc.contributor.localId | A05527 | - |
dc.contributor.localId | A04402 | - |
dc.relation.journalcode | J02805 | - |
dc.identifier.eissn | 1433-8726 | - |
dc.identifier.pmid | 30734074 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00345-019-02658-1 | - |
dc.subject.keyword | Castration resistant | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | Lymphocytes | - |
dc.subject.keyword | Neutrophils | - |
dc.subject.keyword | Prostatic neoplasms | - |
dc.subject.keyword | Survival | - |
dc.contributor.alternativeName | Koo, Kyo Chul | - |
dc.contributor.affiliatedAuthor | 구교철 | - |
dc.contributor.affiliatedAuthor | 나군호 | - |
dc.contributor.affiliatedAuthor | 이광석 | - |
dc.contributor.affiliatedAuthor | 이종수 | - |
dc.contributor.affiliatedAuthor | 정병하 | - |
dc.contributor.affiliatedAuthor | 하지수 | - |
dc.contributor.affiliatedAuthor | 홍성준 | - |
dc.citation.volume | 37 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2375 | - |
dc.citation.endPage | 2384 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF UROLOGY, Vol.37(11) : 2375-2384, 2019 | - |
dc.identifier.rimsid | 63633 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.